THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pacesetter in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for sufferers with most cancers and autoimmune ailments, in the present day introduced that Pascal Touchon, President and Chief Government Officer, will take part in a hearth chat on the Stifel Digital Cell Remedy Discussion board on Tuesday, July 9, 2024 at 6:45 a.m. PDT / 9:45 a.m. EDT.
A dwell webcast of the presentation can be out there by visiting the Traders and Media part of atarabio.com. An archived replay of the webcast can be out there on the Firm’s web site for 30 days following the dwell presentation.
About Atara Biotherapeutics (NASDAQ:), Inc.
Atara is harnessing the pure energy of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune circumstances that may be quickly delivered to sufferers from stock. With cutting-edge science and differentiated method, Atara is the primary firm on this planet to obtain regulatory approval of an allogeneic T-cell immunotherapy. Our superior and versatile T-cell platform doesn’t require T-cell receptor or HLA gene enhancing and kinds the premise of a various portfolio of investigational therapies that focus on EBV, the foundation explanation for sure ailments, along with next-generation AlloCAR-Ts designed for best-in-class alternatives throughout a broad vary of hematological malignancies and B-cell pushed autoimmune ailments. Atara is headquartered in Southern California. For extra info, go to atarabio.com and comply with @Atarabio on X and LinkedIn.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20240702299482/en/
Investor and Media Relations
Jason Awe, Ph.D.
Senior Director, Company Communications & Investor Relations
(805) 217-2287
[email protected]
Supply: Atara Biotherapeutics, Inc.